Shuttle Pharma doses first three patients in Phase 2 glioblastoma trial; raises $4.5M

Shuttle Pharmaceuticals Holdings, Inc.

First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma; screening for additional patients ongoing.
Paid off entire $4.3M Senior Secured Convertible Note ahead of March 2025 maturity.
Completed $4.5M public offering; proceeds to fund clinical trials and working capital.
Closed $790k convertible note/warrant offering, including $237.5k from CEO Anatoly Dritschilo.
Cash balance $4.1M as of October 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.